GRAIL shares surged 14% on October 16, 2025, following the announcement of a strategic collaboration with Samsung C&T and Samsung Electronics to bring the company’s Galleri multi-cancer early detection test to key Asian markets. Samsung entities are committed to investing $110 million in GRAIL at $70.05 per share, with Samsung C&T securing exclusive distribution rights for South Korea and potential expansion into Japan and Singapore.

The stock jumped another 9% in extended trading, pushing the share price to approximately $90. The deal positions Samsung to integrate GRAIL’s genomic diagnostic technologies into its digital health ecosystem through the Samsung Health platform, potentially providing personalized cancer screening…